Melanotan-1 10mg

The core use of MT-1 10mg is to target and activate melanocyte stem cells (McSCs) in the follicular bulge area of vitiligo patients, driving their proliferation, migration to the epidermal white spot area, differentiation into mature functional melanocytes, rebuilding the epidermal melanocyte network from the root, repairing pigment loss and damage. It is currently the only clinical drug that can directly activate endogenous melanocyte stem cell regeneration, which is different from traditional treatment methods that only stimulate melanocyte synthesis or inhibit immunity, achieving a leap from "inhibitory destruction" to "active regeneration" treatment mode. Vitiligo is essentially a regenerative deficiency disease characterized by depletion of hair follicle melanocyte stem cell reserves, proliferation and differentiation disorders, migration obstruction, and autoimmune destruction of mature melanocytes. Conventional treatment can only partially suppress immunity or mildly promote residual melanocyte function, and cannot repair the stem cell pool. However, MT-1 10mg activates the stem cell regeneration chain through the MC1R signaling pathway, providing a core cell source for vitiligo color restoration.

Melanotan-1 10mg is a highly selective MC1R agonist, with an affinity for MC1R on the surface of melanocytes and mature melanocytes that is 10-100 times that of natural α - MSH. Its half-life is extended to 2-3 weeks, and a dose of 10mg can stably activate the MC1R signaling pathway for 21 days, continuously driving the regeneration process.
Receptor binding and signal initiation: MT-1 10mg specifically binds to MC1R (G protein coupled receptor) on the surface of McSCs, activating G α s protein, increasing adenylate cyclase (AC) activity by 5-8 times, and increasing intracellular cAMP concentration by 10-20 times.
PKA activation and transcriptional regulation: cAMP activates protein kinase A (PKA), PKA phosphorylates microphthalmia associated transcription factor (MITF), enhances MITF nuclear translocation, upregulates MITF expression by 3-5 times, and becomes the core transcriptional switch for melanocyte regeneration.

Stem cell proliferation activation: MITF upregulates the expression of Cyclin D1 and CDK4, inhibits p21/P27 tumor suppressor, drives McSCs from G0 phase into the cell cycle, increases proliferation rate by 40-60%, and significantly increases the number of hair follicle stem cells.
Enhanced migration ability: MITF activates matrix metalloproteinases (MMP-2, MMP-9) and chemokine receptors (CXCR4), degrading the hair follicle basement membrane and extracellular matrix. The migration ability of McSCs is increased by 3-5 times, and they migrate directionally to the white spot area of the epidermis.
Differentiation and maturation drive: MITF upregulates key melanin synthesis enzymes such as tyrosinase (TYR), tyrosinase related protein 1 (TRP-1), and TRP-2, inducing McSCs to differentiate into mature functional melanocytes with normal melanin synthesis and transport capabilities.
Regeneration microenvironment optimization: Activate keratinocytes to secrete stem cell factor (SCF), fibroblast growth factor (FGF), and endothelin-1 (ET-1), construct a microenvironment that supports melanocyte regeneration, and further promote stem cell survival and differentiation.

Enhancement of stem cell proliferation: After treatment with 10mg MT-1, the number of McSCs in the follicular bulge area increased by 2-3 times, and the stem cell proliferation index (Ki-67 positivity rate) increased from baseline 5-8% to 25-35%, significantly repairing the depleted stem cell pool.
Maximizing migration efficiency: 10mg is the optimal effective dose, below 10mg there is insufficient signal activation, above 10mg there is no additional regeneration gain and increased risk of side effects; At a dose of 10mg, the efficiency of McSCs migrating to epidermal leukoplakia reached 60-70%, much higher than conventional treatment (10-20%).
Improvement in differentiation and maturation rate: The maturation rate of melanocytes induced by 10mg MT-1 reaches 85-90%, with normal dendritic morphology and melanosome synthesis ability, and a significant increase in the number of functional melanocytes.
Continuity of regeneration guarantee: The 10mg dose lasts for 21 days, and repeated administration every 3 weeks can maintain a continuous regeneration signal, avoiding interruption of stem cell regeneration and ensuring the continuity of the color restoration process.

The core clinical use of melanotan-1 10mg is to significantly accelerate the color restoration speed of vitiligo white spots, improve the color restoration rate, improve the uniformity of color restoration, promote hair color restoration, shorten the treatment cycle, and solve the clinical pain points of traditional treatment such as slow color restoration, low effective rate, difficult hair color restoration, and long treatment period. The 10mg dose is the best effective dose for color restoration, and both monotherapy and combination with NB-UVB show significant color restoration advantages, especially in the treatment of facial and neck white spots, follicular white spots, and stable white spots.
Combined NB-UVB (10mg every 3 weeks x 20 weeks): median onset time for facial and neck white spots is 41 days, and proximal limbs are 46 days; The simple NB-UVB groups were 61 days and 58 days, respectively, with an early start time of 20-12 days and an acceleration of 30-40%.

Follicular leukoplakia: The initiation time of hair discoloration is advanced by 30-50%, and the blackening of hair occurs synchronously with skin discoloration, solving the problem of "skin discoloration and unchanged hair" in traditional treatment.
Phase III RCT (n=200, 10mg+NB-UVB vs NB-UVB): After 20 weeks of treatment, the average VASI score improved by 48.64%, compared to 33.26% in the simple phototherapy group, with a relative increase of 46% (P<0.001).
Stratification of color reproduction rate: 35% of patients had a color reproduction rate ≥ 75%, while only 18% in the group receiving simple phototherapy; The proportion of patients with a color reproduction rate of ≥ 50% reached 62%, while the group receiving simple phototherapy had a rate of 38%.
Site specific color restoration rate: 70-80% for the face and neck, 50-60% for the proximal limbs, and 40-50% for the trunk, significantly better than traditional treatments (40-50% for the face and neck, 20-30% for the limbs).

Optimization of color reproduction mode: Point like color reproduction centered on hair follicles gradually merges into patches, with uniform color reproduction, natural boundaries, no mottled pigmentation, and significantly improved aesthetics.
Color depth and stability: The true melanin content of the compound skin is increased by 3-5 times, and the color is similar to normal skin, which is not easy to fade and has strong stability.
Hair color restoration synchronization: 50-60% of patients achieve complete hair restoration, 30-40% achieve partial restoration, significantly improving appearance.
Traditional NB-UVB: It takes 6-12 months to achieve significant color reproduction; 10mg MT-1+NB-UVB: Significant color fading can be observed at 2-3 months, reaching a plateau at 4-5 months, and the treatment course is shortened by 50%.

Compliance improvement: 10mg implant once every 3 weeks, no need for daily medication, treatment duration rate of over 90%, far higher than traditional topical/oral treatment (50-60%).
Low dose (<10mg): Insufficient signal activation, color reproduction rate of only 20-30%, delayed start-up time, weak stem cell regeneration effect.
10mg dose: The optimal potency balance, peak color reproduction rate, regenerative effect, and safety are all achieved, and the clinically recommended standard dose.
High dose (>10mg): No additional color gain, increased risk of nausea, dizziness, and excessive skin pigmentation, reduced cost-effectiveness.